Hester Biosciences Limited — Dividend/Bonus, 09-05-2025: Dividend

Hester Biosciences has announced a board meeting to approve the financial results for the quarter and half-year. The Board has proposed a final dividend of ₹7 per equity share (70%), pending shareholder approval. This reflects steady operational gains with standalone PAT up 17% for FY25 and 30% in Q4. The company remains focused on expanding its poultry and animal healthcare segments, bolstered by strong market positions in PPR and Goat Pox vaccines and new product launches to drive future growth. Payment and record dates will follow post-AGM.